Post X-Waiver Substance Use Disorder Training Module 7: Opioid Use Disorder 201

Description

Register now for this online, self-guided course!

This module will first provide a background on the opioid epidemic and its effects on North Carolina. It will then identify the different pharmacological treatments for opioid use disorder (MOUD) and describe the differences in these medications including their efficacy, pharmacology, and historical and political regulation. It then will describe how buprenorphine is prescribed and how opioid withdrawal is managed.

Approximate time to complete the course: 1 hour
Learner content includes: video and corresponding course handouts
Participants have unlimited time to complete this course and access course materials

This training module is part of a training suite that has been developed in accordance with the recommendations from the DEA and SAMHSA for the Medication Access and Training Expansion (MATE) Act. This requirement applies to physicians, physician assistants, nurse practitioners, podiatrists, dentists, and other practitioners that prescribe controlled substances who are applying for or renewing their DEA license after June 27, 2023.

Click here for more information and a full listing of modules available.


MAHEC engages in evaluation activities to better understand the impact of our programs. By registering for this course, you agree that we may use your personal information in evaluative research regarding this program. Any reports published will be de-identified and reported in aggregate format.

With Support From

Target Audience

This program is recommended for physicians, physician assistants, nurse practitioners, podiatrists, dentists, and other practitioners that prescribe controlled substances.

Objectives

• Apply your understanding of the pharmacology of the three FDA approved medications for the treatment of opioid use disorders in using them most effectively
• Demonstrate an understanding of who can prescribe which three FDA approved medications for opioid use disorder
• Analyze the safety of the buprenorphine-naloxone combination product

Faculty

• Stephen A. Wyatt, DO